Effect of Rosiglitazone and Insulin Combination Therapy on Inflammation Parameters and Adipocytokine Levels in Patients with Type 1 DM

Overview

Journal J Diabetes Res

Publisher Wiley

Specialty Endocrinology

Date 2015 Aug 15

PMID 26273677

Citations 4

Authors

Metin Guclu

Ozen Oz Gul

Soner Cander

Oguzkaan Unal

Guven Ozkaya

Emre Sarandol

Canan Ersoy

Affiliations

Soon will be listed here.

Abstract

Aim: To investigate the efficacy of combined therapy of insulin and rosiglitazone on metabolic and inflammatory parameters, insulin sensitivity, and adipocytokine levels in patients with type 1 diabetes mellitus (type 1 DM).

Material And Methods: A total of 61 adults with type 1 DM were randomly and prospectively assigned in open-label fashion to take insulin and rosiglitazone 4 mg/day (n = 30) or insulin alone (n = 31) for a period of 18 weeks while undergoing insulin therapy without acute metabolic complications.

Results: Combination therapy did not significantly improve metabolic and inflammatory parameters, insulin sensitivity, and adiponectin levels. While leptin and resistin levels decreased in both groups (group 1: resistin 6.96 ± 3.06 to 4.99 ± 2.64, P = 0.006; leptin 25.8 ± 17.6 to 20.1 ± 12.55, P = 0.006; group 2: resistin 7.16 ± 2.30 to 5.57 ± 2.48, P = 0.031; leptin 16.72 ± 16.1 to 14.0 ± 13.4, P = 0.007) Hgb and fibrinogen levels decreased only in group 1 (Hgb 13.72 ± 1.98 to 13.16 ± 1.98, P = 0.015, and fibrinogen 4.00 ± 1.08 to 3.46 ± 0.90, P = 0.002). Patients in both groups showed weight gain and the incidence of hypoglycemia was not lower.

Discussion: The diverse favorable effects of TZDs were not fully experienced in patients with type 1 DM. These results are suggesting that insulin sensitizing and anti-inflammatory characteristics of TZDs were likely to be more pronounced in patients who were not totally devoid of endogenous insulin secretion.

Citing Articles

New Developments in T Cell Immunometabolism and Therapeutic Implications for Type 1 Diabetes.

Zhang M, Zhou Y, Xie Z, Luo S, Zhou Z, Huang J Front Endocrinol (Lausanne). 2022; 13:914136.

PMID: 35757405 PMC: 9226440. DOI: 10.3389/fendo.2022.914136.

Glucose-Lowering Therapy beyond Insulin in Type 1 Diabetes: A Narrative Review on Existing Evidence from Randomized Controlled Trials and Clinical Perspective.

Aberer F, Pieber T, Eckstein M, Sourij H, Moser O Pharmaceutics. 2022; 14(6).

PMID: 35745754 PMC: 9229408. DOI: 10.3390/pharmaceutics14061180.

In Silico Analysis of Coding/Noncoding SNPs of Human Gene and Characterization of Their Impact on Resistin Stability and Structure.

Elkhattabi L, Morjane I, Charoute H, Amghar S, Bouafi H, Elkarhat Z J Diabetes Res. 2019; 2019:4951627.

PMID: 31236417 PMC: 6545779. DOI: 10.1155/2019/4951627.

Short-term insulin intensive therapy decreases MCP-1 and NF-κB expression of peripheral blood monocyte and the serum MCP-1 concentration in newlydiagnosed type 2 diabetics.

Lin Y, Ye S, He Y, Li S, Chen Y, Zhai Z Arch Endocrinol Metab. 2018; 62(2):212-220.

PMID: 29641741 PMC: 10118989. DOI: 10.20945/2359-3997000000029.

References

Frystyk J, Tarnow L, Hansen T, Parving H, Flyvbjerg A . Increased serum adiponectin levels in type 1 diabetic patients with microvascular complications. Diabetologia. 2005; 48(9):1911-8. DOI: 10.1007/s00125-005-1850-z. View

Bhat R, Bhansali A, Bhadada S, Sialy R . Effect of pioglitazone therapy in lean type 1 diabetes mellitus. Diabetes Res Clin Pract. 2007; 78(3):349-54. DOI: 10.1016/j.diabres.2007.04.012. View

Verrotti A, Basciani F, Morgese G, Chiarelli F . Leptin levels in non-obese and obese children and young adults with type 1 diabetes mellitus. Eur J Endocrinol. 1998; 139(1):49-53. DOI: 10.1530/eje.0.1390049. View

Parulkar A, Pendergrass M, Lee T, Fonseca V . Nonhypoglycemic effects of thiazolidinediones. Ann Intern Med. 2001; 134(1):61-71. DOI: 10.7326/0003-4819-134-1-200101020-00014. View

Nokoff N, Rewers M, Green M . The interplay of autoimmunity and insulin resistance in type 1 diabetes. Discov Med. 2012; 13(69):115-22. PMC: 5074679. View

Chiarelli F, Di Marzio D . Peroxisome proliferator-activated receptor-gamma agonists and diabetes: current evidence and future perspectives. Vasc Health Risk Manag. 2008; 4(2):297-304. PMC: 2496982. DOI: 10.2147/vhrm.s993. View

Azar S, Zalloua P, Zantout M, Shahine C, Salti I . Leptin levels in patients with type 1 diabetes receiving intensive insulin therapy compared with those in patients receiving conventional insulin therapy. J Endocrinol Invest. 2002; 25(8):724-6. DOI: 10.1007/BF03345107. View

Orchard T, Olson J, Erbey J, Williams K, Forrest K, Smithline Kinder L . Insulin resistance-related factors, but not glycemia, predict coronary artery disease in type 1 diabetes: 10-year follow-up data from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes Care. 2003; 26(5):1374-9. DOI: 10.2337/diacare.26.5.1374. View

Kilpatrick E, Rigby A, Atkin S . Insulin resistance, the metabolic syndrome, and complication risk in type 1 diabetes: "double diabetes" in the Diabetes Control and Complications Trial. Diabetes Care. 2007; 30(3):707-12. DOI: 10.2337/dc06-1982. View

10.

Schaumberg D, Glynn R, Jenkins A, Lyons T, Rifai N, Manson J . Effect of intensive glycemic control on levels of markers of inflammation in type 1 diabetes mellitus in the diabetes control and complications trial. Circulation. 2005; 111(19):2446-53. DOI: 10.1161/01.CIR.0000165064.31505.3B. View

11.

Strowig S, Raskin P . The effect of rosiglitazone on overweight subjects with type 1 diabetes. Diabetes Care. 2005; 28(7):1562-7. DOI: 10.2337/diacare.28.7.1562. View

12.

Shalev A, Patterson N, Hirshberg B, Rother K, Harlan D . Resistin serum levels in type 1 diabetes pre- and post-islet transplantation. Metabolism. 2004; 53(4):403-4. DOI: 10.1016/j.metabol.2003.11.014. View

13.

Galler A, Gelbrich G, Kratzsch J, Noack N, Kapellen T, Kiess W . Elevated serum levels of adiponectin in children, adolescents and young adults with type 1 diabetes and the impact of age, gender, body mass index and metabolic control: a longitudinal study. Eur J Endocrinol. 2007; 157(4):481-9. DOI: 10.1530/EJE-07-0250. View

14.

Cleland S, Fisher B, Colhoun H, Sattar N, Petrie J . Insulin resistance in type 1 diabetes: what is 'double diabetes' and what are the risks?. Diabetologia. 2013; 56(7):1462-70. PMC: 3671104. DOI: 10.1007/s00125-013-2904-2. View

15.

Karalliedde J, Buckingham R . Thiazolidinediones and their fluid-related adverse effects: facts, fiction and putative management strategies. Drug Saf. 2007; 30(9):741-53. DOI: 10.2165/00002018-200730090-00002. View

16.

Fujisawa K, Nishikawa T, Kukidome D, Imoto K, Yamashiro T, Motoshima H . TZDs reduce mitochondrial ROS production and enhance mitochondrial biogenesis. Biochem Biophys Res Commun. 2008; 379(1):43-8. DOI: 10.1016/j.bbrc.2008.11.141. View

17.

Quinn C, Hamilton P, Lockhart C, McVeigh G . Thiazolidinediones: effects on insulin resistance and the cardiovascular system. Br J Pharmacol. 2007; 153(4):636-45. PMC: 2259217. DOI: 10.1038/sj.bjp.0707452. View

18.

Goldberg R, Kendall D, Deeg M, Buse J, Zagar A, Pinaire J . A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care. 2005; 28(7):1547-54. DOI: 10.2337/diacare.28.7.1547. View

19.

Singh S, Loke Y, Furberg C . Thiazolidinediones and heart failure: a teleo-analysis. Diabetes Care. 2007; 30(8):2148-53. DOI: 10.2337/dc07-0141. View

20.

Williams K, Erbey J, Becker D, Arslanian S, Orchard T . Can clinical factors estimate insulin resistance in type 1 diabetes?. Diabetes. 2000; 49(4):626-32. DOI: 10.2337/diabetes.49.4.626. View